Skip to main content
. 2017 Aug 8;8(48):84572–84578. doi: 10.18632/oncotarget.20028

Figure 2. Relative risk for (A) Any grade and (B) ≥ 3 fatigue in patients treated with Abiraterone or Enzalutamide.

Figure 2